Spectral Medical Inc T.EDT

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

[TechOne]

Kidney Care Separation Update

Baxter’s preparations are progressing for the proposed separation of its Kidney Care segment into a standalone company to be named Vantive. As a standalone entity, Vantive is expected to benefit from a heightened strategic focus and the ability to pursue its unique investment priorities, to emerge better positioned to accelerate growth and innovation, and to create incremental value for its patients, clinicians, investors, and other stakeholder communities.

Chris Toth, executive vice president and group president, Kidney Care, and designated chief executive officer of Vantive, continues to build out his senior management team. Recently, he named Matt Harbaugh as vice president, Finance, Kidney Care and designated chief financial officer of Vantive. Mr. Harbaugh was previously chief financial officer at NuVasive Inc.
https://finance.yahoo.com/news/baxter-reports-fourth-quarter-full-121500976.html

[BlueJays9293]

What caught my eye from the transcript: Danielle Antalffy of UBS is on the line with a question. Please state your question.   Danielle Antalffy Thanks, everyone. Good morning. And just a quick question on sort of what the longer-term focus is post Kidney Care? I assume we’ll get some more color here once we have the pre-spin Analyst Day. But just at a high level, Joe and

[hmmmmmmmm]

Nice. From their presentation they def need inorganic growth ops.

[BlueJays9293]

I really liked that comment that they want Vantive to broaden into more "multi organ support therapies." Just as a reminder, slide #12 from Spectral says; PMX patients had 14 fewer days on a Ventilator (lungs) versus SOC. PMX patients had 9 fewer days of dialysis (kidneys) versus SOC. PMX patients blood pressure (heart) improved by 5.0 mmHg. Helping the Lungs, Kidneys, and Heart

[hmmmmmmmm]

We also know endotoxin burden is very significant in burn patients, and in open heart surgery patients. There are studies in Japan dating back to 2008 using PMX for these aplications.  A company like Baxter/ Vantive would have the ability and resources to immediately apply for add on studies- adding to their "multi organ support therapies" windfall. 

[BlueJays9293]

Open heart surgery is where the real pot of gold is for PMX in my opinion.  Over 500K open heart surgeries are performed per year in the US, so roughly 4 times the market potential of PMX for septic shock.  There's something about rerouting a patients blood to the heart-lung bypass machine that contaminates the blood with endotoxin.  Yeah that add on study needs to start

[mercedesman]

Not to mention myocarditis.  Several studies have shown that treatments with PMX benefits these patients ( lowers mortality)  I'll try to find the latest and post it.  Myocarditis is inflammation of the heart muscle and pericarditis is inflammation of the lining outside of the heart. In both cases, the body's immune system is causing inflammation in